First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis

Abstract Background A first-line biologic treatment for metastatic colorectal cancer (mCRC) is still controversial. We, therefore, performed a meta-analysis to determine the efficacy of first-line cetuximab versus bevacizumab for RAS and BRAF wild-type mCRC. Methods In March 2018, an electronic sear...

Full description

Bibliographic Details
Main Authors: Bobo Zheng, Xin Wang, Mingtian Wei, Quan Wang, Jiang Li, Liang Bi, Xiangbing Deng, Ziqiang Wang
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Cancer
Subjects:
First line
Cetuximab
Bevacizumab
Wild type
Metastatic colorectal cancer
Online Access:http://link.springer.com/article/10.1186/s12885-019-5481-z

Internet

http://link.springer.com/article/10.1186/s12885-019-5481-z

Similar Items